Company: PIII
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001628280-25-015305
Chunk: 169

Company: P3 Health Partners Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 7
Chunk 169
---
 occur that cannot currently be estimated. When only a range of amounts is reasonably estimable and no amount within the range is more likely than another, the low end of the range is recorded. The Company expenses costs associated with loss contingencies, including any related legal fees, as they are incurred. Due to the inherent uncertainties surrounding gain contingencies, the Company does not recognize potential gains until realized.

P3 Health Partners Inc. | 2024 Form 10-K | 86

Net Loss per ShareBasic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share attributable to common stockholders adjusts basic earnings per share for the potentially dilutive impact of warrants, stock options, restricted stock units, restricted stock awards, and Common Units convertible into shares of Class A common stock during the period by applying the treasury stock method or if-converted method, as applicable. Cash and Restricted CashCash includes all cash and liquid investments with an initial maturity of three months or less. Cash deposits held in accounts at each financial institution are insured up to $250,000 by the Federal Deposit Insurance Corporation (“FDIC”). The Company maintains its cash in bank deposit accounts that, at times, may exceed FDIC insured limits. Management does not expect any losses to occur on such accounts.As of December 31, 2024 and 2023, the Company had cash of $38.8 million and $36.3 million, respectively, deposited at banking institutions which are subject to the FDIC insured limit.Restricted cash is held for a specific purpose (such as payment of healthcare claims) and is thus not available to the Company for immediate or general business use. As of December 31, 2024 and 2023, the Company had restricted cash of $5.3 million and $4.6 million, respectively.Revenue RecognitionThe Company categorizes revenue based on various factors, such as the nature of contracts, as follows:Revenue TypeYear Ended December 31, 2024% of TotalYear Ended December 31, 2023% of Total(dollars in thousands)Capitated revenue$1,483,602 98.9 %$1,252,309 98.9 %Other patient service revenue:Clinical fees & insurance revenue5,934 0.4 5,192 0.3 Care coordination / management fees10,563 0